Background:The role of ZNF165 in only a few tumors has been reported. ZNF165
plays an important role in liver cancer, gastric cancer, and breast cancer, especially in regulating
the immune microenvironment, promoting tumor cell proliferation and migration, and serving as a
potential target for immunotherapy.Objective:This study aimed to enhance an understanding of how the ZNF165 gene functions and
influences cancer development.Methods:Using a suite of online resources, including TIMER, TCGA, GTEx, GEPIA2, cBioPortal,
TIMER2, STRING, DAVID, RNAactDrug, CancerSEA, and UCSC, along with comprehensive
statistical analyses, we conducted a thorough investigation of the pan-cancer landscape of ZNF165.
This study encompassed an assessment of ZNF165 levels, their associations with patient outcomes,
and clinical correlates. We examined the interplay between ZNF165 and key cancer biomarkers,
such as Microsatellite Instability (MSI), Tumor Mutational Burden (TMB), immune cell
infiltration, and the expression of immune checkpoint genes. We delved into the genetic variations
of ZNF165, its biological roles across various cancer types, and its potential links to drug responsiveness.
We analyzed single-cell expression patterns of ZNF165 and their implications for the
functional dynamics of cancer. We employed quantitative Reverse Transcription PCR (qRT-PCR)
to measure ZNF165 levels in Ovarian Cancer (OC) cell lines.Results:ZNF165 expression displayed aberrations across a diverse range of human cancers and
exhibited correlations with clinical stages. High ZNF165 expression in KIRC, KIRP, STAD, and
UCEC was significantly associated with poor overall survival. ZNF165 has encouraging diagnostic
value in specific tumor types, with gene amplification identified as the predominant genetic alteration.
Our analysis further uncovered significant associations between ZNF165 levels and MSI
across three distinct cancer types, as well as with TMB in six different malignancies. We detected
substantial correlations between ZNF165 levels and immune cell infiltration, as well as the expression
of immune checkpoint genes. ZNF165 was found to be involved in several prevalent signaling
pathways across various cancer types. ZNF165 may potentially contribute to chemotherapy
and chemoresistance, and was observed to be involved in cancer progression. A ceRNA regulatory
network involving AFDN-DT, miR-191-5p, and ZNF165 was constructed for OC, revealing significantly
elevated ZNF165 levels in OC cell lines. Dysregulated ZNF165 expression across a
spectrum of malignancies might play a role in cancer initiation and advancement via multiple biological
pathways.Conclusion:ZNF165 may serve as a promising therapeutic target for the treatment of cancer in human
patients.